Bangalore, India -- (SBWIRE) -- 04/06/2018 -- Alcoholic Hepatitis - Pipeline Review, H1 2018, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights
Alcoholic Hepatitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 69 pages "Alcoholic Hepatitis - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Alcoholic Hepatitis - Overview, Alcoholic Hepatitis - Therapeutics Development, Alcoholic Hepatitis - Therapeutics Assessment, Alcoholic Hepatitis - Companies Involved in Therapeutics Development, Alcoholic Hepatitis - Drug Profiles, Alcoholic Hepatitis - Dormant Projects, Appendix. This report Covered Companies - DURECT Corp, Generon (Shanghai) Corp Ltd, Gilead Sciences Inc, GRI Bio Inc, Immuron Ltd, Intercept Pharmaceuticals Inc, Promethera Biosciences SA, Verlyx Pharma Inc, Vital Therapies Inc.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/alcoholic-hepatitis-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Phenylketonuria (PKU) - Pipeline Review, H2 2017 - Visit at - https://www.drugpipeline.net/global-markets-direct/phenylketonuria-pku-pipeline-review-h2-2017

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2017 - Visit at - https://www.drugpipeline.net/global-markets-direct/onychomycosis-tinea-unguium-pipeline-review-h2-2017

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.